nach oben

Erschienen in:

01.07.2009 | Short Communication

Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells

verfasst von: Danita H. Schuurhuis, W. Joost Lesterhuis, Matthijs Kramer, Maaike G. M. Looman, Maaike van Hout-Kuijer, Gerty Schreibelt, A. C. Inge Boullart, Erik H. J. G. Aarntzen, Daniel Benitez-Ribas, Carl G. Figdor, Cornelis J. A. Punt, I. Jolanda M. de Vries, Gosse J. Adema

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Tumor-derived peptides are used frequently as antigen (Ag) source in dendritic cell (DC) therapy in cancer patients. An alternative is to load DC with tumor-associated Ag (TAA)-encoding RNA. RNA-loading obviates prior knowledge of CTL and Th epitopes in the Ag. Multiple epitopes for many HLA alleles (both MHC class I and class II) are encoded by the RNA and loading is independent of the patient’s HLA make-up. Herein, we determined the optimal conditions for mRNA-electroporation of monocyte-derived DC for clinical application in relation to different maturation cocktails. The data demonstrate that TAA carcinoembryonic antigen, gp100 and tyrosinase are expressed already 30 min after electroporation with the encoding mRNA. Moreover, gp100-specific CTL are activated by gp100 mRNA-electroporated DC. Importantly, we show here that the presence of polyinosinic–polycytidylic acid [poly(I:C)] in the maturation cocktail prevents effective protein expression of the electroporated mRNA as well as subsequent CTL recognition. This effect of poly(I:C) correlates with the induction of IFN-induced genes and innate anti-viral effector molecules in DC. Together these data show that electroporation of mature DC with TAA-encoding mRNA is attractive for use in DC vaccination protocols in cancer patients, but protein expression should be tested for each maturation cocktail.

Nur mit Berechtigung zugänglich

Lesterhuis WJ, Aarntzen EH, de Vries IJ et al (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66:118–134PubMedCrossRef

Tuyaerts S, Aerts JL, Corthals J et al (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56:1513–1537PubMedCrossRef

Jonuleit H, Kuhn U, Muller G et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135–3142PubMedCrossRef

Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146PubMedCrossRef

Sporri R, Reis e Sousa C (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4⁺ T cell populations lacking helper function. Nat Immunol 6:163–170PubMedCrossRef

Boullart AC, Aarntzen EH, Verdijk P et al (2008) Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E(2) results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57:1589–1597PubMedCrossRef

Zobywalski A, Javorovic M, Frankenberger B et al (2007) Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 5:18PubMedCrossRef

de Vries IJ, Bernsen MR, Lesterhuis WJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779–5787PubMedCrossRef

Fay JW, Palucka AK, Paczesny S et al (2006) Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 55:1209–1218PubMedCrossRef

10.

Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedCrossRef

11.

Schuler-Thurner B, Schultz ES, Berger TG et al (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279–1288PubMedCrossRef

12.

Bonehill A, Heirman C, Tuyaerts S et al (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172:6649–6657PubMed

13.

Nair SK, Morse M, Boczkowski D et al (2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235:540–549PubMedCrossRef

14.

Schaft N, Dorrie J, Thumann P et al (2005) Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 174:3087–3097PubMed

15.

Grunebach F, Muller MR, Nencioni A, Brossart P (2003) Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 10:367–374PubMedCrossRef

16.

Van Meirvenne S, Straetman L, Heirman C et al (2002) Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 9:787–797PubMedCrossRef

17.

Javorovic M, Pohla H, Frankenberger B, Wolfel T, Schendel DJ (2005) RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol Ther 12:734–743PubMedCrossRef

18.

Michiels A, Tuyaerts S, Bonehill A et al (2005) Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 12:772–782PubMedCrossRef

19.

Bakker AB, Schreurs MW, Tafazzul G et al (1995) Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 62:97–102PubMedCrossRef

20.

de Vries IJ, Adema GJ, Punt CJ, Figdor CG (2005) Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med 109:113–126PubMed

21.

Lesterhuis WJ, de Vries IJ, Schuurhuis DH et al (2006) Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol 17:974–980PubMedCrossRef

22.

Bakker AB, Schreurs MW, de Boer AJ et al (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005–1009PubMedCrossRef

23.

Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA (1992) Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 148:638–643PubMed

24.

Kawakami Y, Eliyahu S, Delgado CH et al (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458–6462PubMedCrossRef

25.

Romani N, Reider D, Heuer M et al (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196:137–151PubMedCrossRef

26.

Mailliard RB, Wankowicz-Kalinska A, Cai Q et al (2004) Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934–5937PubMedCrossRef

27.

Kramer M, Schulte BM, Toonen LW et al (2008) Phagocytosis of picornavirus-infected cells induces an RNA-dependent antiviral state in human dendritic cells. J Virol 82:2930–2937PubMedCrossRef

28.

Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475–480PubMedCrossRef

29.

Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296–306PubMedCrossRef

30.

de Vries IJ, Lesterhuis WJ, Scharenborg NM et al (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091–5100PubMed

31.

Roberts WK, Clemens MJ, Kerr IM (1976) Interferon-induced inhibition of protein synthesis in L-cell extracts: an ATP-dependent step in the activation of an inhibitor by double-stranded RNA. Proc Natl Acad Sci USA 73:3136–3140PubMedCrossRef

32.

Hovanessian AG, Justesen J (2007) The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′instead of 3′-5′ phosphodiester bond formation. Biochimie 89:779–788PubMedCrossRef

Titel: Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells
verfasst von: Danita H. Schuurhuis
W. Joost Lesterhuis
Matthijs Kramer
Maaike G. M. Looman
Maaike van Hout-Kuijer
Gerty Schreibelt
A. C. Inge Boullart
Erik H. J. G. Aarntzen
Daniel Benitez-Ribas
Carl G. Figdor
Cornelis J. A. Punt
I. Jolanda M. de Vries
Gosse J. Adema
Publikationsdatum: 01.07.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0626-y

Springer Medizin

Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

Reduced levels of recent thymic emigrants in acute myeloid leukemia patients

Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity

Immunotherapy: from basic research to clinical applications

FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie